Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Low-dose Bevacizumab in Relapsed Oligodendroglioma
NCT05512351Phase 2Recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Oligodendroglioma (OG), sponsored by Henan Provincial People's Hospital. Started Dec 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Oligodendroglioma (OG)
Beyond the preview
Go deeper on NCT05512351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512351.